

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



VOLUNTARY ANNOUNCEMENT MEMORANDUM OF UNDERSTANDING ON POSSIBLE COOPERATION

This announcement is made by China NT Pharma Group Company Limited (the “**Company**”, together with its subsidiaries the “**Group**”) on a voluntary basis to provide its shareholders and potential investors with updated information in relation to the latest business development of the Group.

MEMORANDUM OF UNDERSTANDING ON POSSIBLE COOPERATION

The Board (the “**Board**”) of Directors (the “**Directors**”) of the Company is pleased to announce that in order to signify the mutual intention to cooperate, on 9 October 2023 (after trading hours), the Company and Global New Normal Anti-Inflation Limited Partnership Fund (the “**Global New Normal Fund**”) entered into a non-legally binding Memorandum of Understanding on Possible Cooperation (the “**MOU**”). According to the MOU, the Company and the Global New Normal Fund are willing to have possible cooperation on the Group’s business in the field of orthopedics. The Global New Normal Fund will provide the greatest possible supports if the Group carries out acquisitions of suitable products in the field of orthopedic, so that the products line of the Group can be enriched and the Group also can rapidly expand the market share in the field of orthopedic. The Company is preparing to become a leader in the huge market of orthopedics.

INFORMATION ABOUT THE GLOBAL NEW NORMAL FUND

The Global New Normal Fund is a private equity fund established in Hong Kong in the form of a limited partnership in accordance with the Limited Partnership Fund Ordinance (Chapter 637) of Hong Kong.

To the best of the Directors' knowledge, information and belief, having made all reasonable enquiries, The Global New Normal Fund and its ultimate beneficial owners are third parties independent of the Company and its connected persons (as defined under the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "Listing Rules")) as at the date of this announcement.

REASONS FOR AND BENEFITS OF THE MOU

In view of the fact that the Group has gone through a round of restructuring and transformation, the Group takes this opportunity to find a profit breakthrough point and will make every effort to transform focusing on pharmaceutical products and health care products in the field of orthopedic. The Group is going to create a new sales platform in order to provide a series of products and delivery services which is more safety, more effectiveness, more convenience to the people with needs in China, especially for elderly people and sportsmen. Based on the Group's outstanding performance in the sales of orthopedic pharmaceutical products in the past few years and its in-depth understanding of the orthopedic pharmaceutical products market, the Board of Directors believes that the MOU offers a good support for the Group to develop the above-mentioned business and full of confidence a better future in the field of orthopedic can be created.

Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
China NT Pharma Group Company Limited
NG Tit
Chairman

Hong Kong, 9 October 2023

As at the date of this announcement, the executive Directors are Mr. Ng Tit and Ms. Chin Yu; the non-executive Director is Dr. Qian Wei; and the independent non-executive Directors are Mr. Yu Tze Shan Hailson, Dr. Zhao Yubiao, and Mr. Ng Ming Kwan.